Drug trial tests new approach to calm sarcoidosis inflammation
NCT ID NCT02134717
Summary
This study tested whether the drug maraviroc could reduce harmful inflammation in the lungs of people with active sarcoidosis. Three participants took maraviroc for six weeks. Researchers compared immune cells from lung washings before and after treatment to see if the drug changed inflammation levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.